Transition Bio Overview

  • Founded
  • 2020

Founded
  • Status
  • Private

  • Employees
  • 35

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $50M

  • Investors
  • 5

Transition Bio General Information

Description

Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for human health care advancement. The company harnesses droplet microfluidic approaches and protein biophysics platforms to characterize condensates with unprecedented precision, enabling medical practitioners to map condensates in molecular detail.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 21 Erie Street
  • Suite C
  • Cambridge, MA 02139
  • United States
+1 (917) 000-0000

Transition Bio Timeline

20212022
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Transition Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 02-Jun-2022 $50M 0000 00000 Completed Generating Revenue
1. Seed Round 01-Sep-2020 000 000 0000 Completed Startup
To view Transition Bio’s complete valuation and funding history, request access »

Transition Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00 00 00 00.000
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Transition Bio’s complete cap table history, request access »

Transition Bio Executive Team (8)

Name Title Board Seat Contact Info
Gregory Miller Chief Executive Officer & Board Member
Martin Kulander Chief Operating Officer
Samuel Cohen Co-Founder & Board Member
Peter George-Hyslop Scientific Co-Founder
Sarah Teichmann Scientific Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

Transition Bio Board Members (9)

Name Representing Role Since
Al Sandrock Self Board Member 000 0000
David Weitz Ph.D Self Co-Founder & Board Member 000 0000
David Zimble Transition Bio Board Member 000 0000
George Martin Self Board Member 000 0000
Gregory Miller Transition Bio Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Transition Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Transition Bio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bristol-Myers Squibb Corporation Minority 000 0000 000000 0
Magnetic Ventures Venture Capital Minority 000 0000 000000 0
Northpond Ventures Venture Capital Minority 000 0000 000000 0
Taiho Ventures Corporate Venture Capital Minority 000 0000 000000 0
Lifeforce Capital Venture Capital Minority 000 0000 000000 0
To view Transition Bio’s complete investors history, request access »